Operational Resilience and Cost Reduction
Implemented a comprehensive cost reduction program and consolidated sites, enhancing global organizational footprint. Successfully transferred Cavro component production to facilities in Morgan Hill, California, and Penang, Malaysia, and closed the San Jose site.
Innovation and Product Launches
Advanced product portfolio with significant launches in genomics, proteomics, and cell biology. Previewed groundbreaking multiomics liquid handling workstation, Veya, and expanded digital ecosystem to enhance laboratory productivity.
Sustainability Initiatives
Completed a climate scenario risk analysis and integrated ESG data management into finance function. Increased purchase of electricity from renewable sources to 87%.
Financial Performance in Life Sciences
Life Sciences business showed moderate order entry growth in local currencies during the second half of 2024, with consumable sales recovery and strong demand for newly launched products.